Quantum-Si incorporated (QSI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal strong financial performance with an 84% revenue increase and a 58% gross margin. Management is optimistic about growth, especially in Q4, and is implementing flexible sales models to overcome capital constraints. The company is focused on innovation and market expansion, particularly in pharma and biotech. Despite some unclear responses, the overall sentiment is positive, supported by strategic product launches and a solid cash position. The stock price is likely to experience a positive movement in the next two weeks.
Key Financial Performance
Revenue Revenue for Q2 2025 was $591,000, a decrease year-over-year due to capital market headwinds driven by uncertainty in NIH funding. This was a full impact compared to partial impact in Q1 2025.
Gross Profit Gross profit for Q2 2025 was $351,000, with a gross margin of 59%. The margin includes a 13% benefit from inventory carried at low or no value.
Operating Expenses GAAP total operating expenses for Q2 2025 were $30.5 million, up from $26.8 million in Q2 2024. Adjusted operating expenses were $23.8 million, slightly down from $24.4 million in Q2 2024, reflecting tight cost controls.
Cash and Investments As of June 30, 2025, the company had $214.2 million in cash, cash equivalents, and investments in marketable securities, providing a strong financial position.
Dividend and Interest Income Dividend and interest income for Q2 2025 was $2.3 million, down from $2.9 million in Q2 2024, reflecting lower interest rates and lower invested balances.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Platinum Pro instrument: Launched expanded acquisition options to address capital sales headwinds, allowing customers to acquire instruments without upfront capital. Secured first few customers under this model, driving consumable purchases.
Version 4 sequencing kit: Expected to launch in Q3 2025, increasing proteome coverage and enabling higher multiplexing levels with 24 barcodes.
Version 3 library preparation kit: On track for launch by end of 2025, reducing sample input quantity by 100-fold, enabling broader biological sample processing.
Proteus platform: Development progressing well, with expected launch in H2 2026. Achieved milestones in fluorescent dye development and wafer-scale surface chemistry processing.
PTM detection kits: Feasibility achieved for site-specific peptide-linked PTM detection, transferred to product development for commercialization.
Pharma and biotech market: Doubled funnel of opportunities from 30 to 60 in Q2 2025. Customers in this segment are consistent buyers of consumables.
Revenue: Q2 2025 revenue was $591,000, impacted by NIH funding uncertainties and reduced capital purchases by U.S. academic labs.
Gross margin: 59% in Q2 2025, with variability expected due to commercialization efforts and inventory adjustments.
Operating expenses: Adjusted operating expenses were $23.8 million in Q2 2025, reflecting tight cost controls and funding for innovation.
Cash position: Ended Q2 2025 with $214.2 million in cash and marketable securities, with runway into Q2 2028 after a $50 million capital raise in July.
Installed base growth: Focus on growing installed base to drive consumable sales and scientific validation, leveraging favorable production costs and strong balance sheet.
AI in recognizer design: Utilized AI to accelerate amino acid recognizer development, achieving specifications within one design cycle.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Capital Market Headwinds: The company is facing significant challenges due to uncertainties in NIH funding, which has led to a near halt in capital purchases by U.S. academic labs. This has negatively impacted revenue, particularly from capital sales of new instruments.
Longer Sales Cycles in Pharma and Biotech: While the company has doubled its funnel of opportunities in the pharma and biotech sectors, the longer sales cycles in these markets pose a challenge to immediate revenue generation.
Dependence on Consumable Revenue: The company is constrained by its reliance on consumable revenue, which is limited by the current single instrument acquisition model. This model restricts the number of users who can adopt the technology.
Litigation Costs: The company incurred approximately $3.4 million in expenses related to the Delaware stockholder litigation, which could impact financial performance.
Tariff and Import Risks: Although currently minor, the company is monitoring potential impacts of tariffs on inventory acquisition costs and customer purchases, which could pose future risks.
Uncertain Financial Guidance: Due to the ongoing NIH funding uncertainties and the early stages of new capital acquisition models, the company is unable to provide clear top-line financial guidance, adding to investor uncertainty.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company is optimistic about growing its customer base using a mix of instrument acquisition options, which is expected to drive consumable revenue. However, the company refrains from providing detailed top-line financial guidance until there is more clarity on the NIH funding environment and the momentum of new acquisition models.
Product Launches: The version 4 sequencing kit is expected to launch during the current quarter, and the version 3 library preparation kit is on track for launch by the end of 2025. The Proteus platform is expected to launch in the second half of 2026, with significant advancements in capabilities.
Market Trends and Opportunities: The company sees long-term market opportunities in proteomics and is optimistic about the potential for growth in pharma and biotech segments, despite current capital market headwinds. The company is also focusing on creating a large installed base of active users to drive long-term value.
Capital Expenditures and Financial Strength: The company has revised its annual estimate for adjusted operating expenses to $98 million or less and expects total cash use to be $95 million or less for 2025. The company anticipates its cash balance, along with recent capital raises, to provide financial runway into the second quarter of 2028.
Technological Advancements: The company is making progress in its innovation roadmap, including AI-based amino acid recognizer design and post-translational modification detection kits, which are expected to enhance research capabilities and system performance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend and Interest Income: In the second quarter of 2025, dividend and interest income was $2.3 million compared to $2.9 million in the second quarter of 2024. For the six months ended June 30, 2025, it was $4.9 million compared to $6.5 million in the same period in 2024. This reflects lower interest rates year-over-year as well as relatively lower invested balances.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much of the $600,000 for 2Q is overseas and how much is in pharma biotech?
A:The company does not break out the distribution by pharma, biotech, or specific segments. However, historically, 65% of the installed base is outside the U.S., and 35% is in the U.S., encompassing various customer types such as academics, industrial, pharma, biotech, and government research labs.
Q:Is $500,000 to $600,000 the bottom, and should we expect growth from here?
A:Management is optimistic that this is the bottom and expects to start building out of it. However, they do not anticipate instant improvement in Q3 due to the time required to grow consumable revenue and capital sales. They expect better acceleration into Q4, driven by a larger installed base, pull-through, and potential cyclical capital sales.
Q:What does a typical placement look like under the new model?
A:Several models are offered: capital purchase, reagent rental with minimum consumable commitments, third-party leasing, and selective machine placements. For placements, machines are provided on a short-term basis, with the option to rotate them if consumable revenue is insufficient. Customers using the machines may convert to capital sales or rentals over time.
Q:Do the new acquisition opportunities increase leads compared to typical capital sales?
A:It is too early to determine if leads have increased. Initial data suggests that customers who were already engaged in the sales process but faced capital constraints are now pursuing alternate placement models. This approach may improve the win rate rather than increasing the number of leads.
Q:What is the delta in missed opportunities due to capital funding constraints?
A:Management did not speculate on the exact number of missed opportunities. They emphasized that the sales force is still incentivized to prioritize capital sales and that alternate models are used only when capital sales are not possible.
Q:Is the company getting enough information from scientific publications and consumable data to improve product offerings?
A:Yes, the company is using customer feedback and field data to guide improvements, such as the version 3 library prep kit with lower sample input. These enhancements aim to address customer needs across various segments, including academic, pharma, and biotech.
Q:How long will the new capital acquisition options be available, and will they apply to Proteus?
A:The duration of these options depends on market conditions. Reagent rentals and leases are longer-term (2-3 years), while placements are shorter-term (6 months). Currently, Proteus is planned for capital sales only, but this may change based on market conditions.
Q:How is consumable utilization trending, and what are the expectations?
A:Consumable revenue exceeded internal expectations and has been consistent across market segments. The company believes that alternate acquisition models will help capture and grow consumable revenue, which has shown resilience despite capital constraints.
Q:Which end markets are the new kits and prep launches most suitable for?
A:The new kits, such as the V4 sequencing kit and V3 library prep kit, are designed to address needs in pharma, biotech, and academic research. They aim to improve capabilities for complex biological sample research and expand applications across all segments.
Q:Are the new PTM capabilities addressing current market needs or future opportunities?
A:The new PTM capabilities are designed to address current customer needs and challenges with existing technologies. The company is prioritizing solutions that align with immediate customer requirements while also considering long-term market opportunities.
Q:Is the company considering acquisitions or partnerships to address challenges in the core business?
A:While the company is focused on its core technology and business, it remains open to exploring partnerships, acquisitions, or licensing opportunities that align with its strategy. However, any such decision would be highly selective and based on a high bar for integration and value.
Q:If revenue remains soft, where would the company consider making cuts?
A:The company does not believe it is over-indexed on commercial or R&D teams. It has optimized operating expenses and headcount, focusing on productivity and targeted adjustments. Any future cuts would be carefully analyzed and prioritized based on business needs.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the delta in missed opportunities due to capital funding constraints, stating that it would be speculative to estimate the number. Additionally, they did not provide detailed information about the duration of the new capital acquisition options or specific financial implications for Proteus under these models.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Analyst Day
Hawkins
PTM detection
Research Division
acquisition option
advantage
balance sheet
base mix
base user
binder
candidate
capital headwind
capital sale
concentration
consumables technology
cost Platinum
design
detection technology
die
driver
feasibility wafer
headwind market
input quantity
instrument acquisition
market headwind
mix acquisition
production
program sample
proteome coverage
recognizer development
road map
set barcodes
state
technology research
term value
wafer scale
QSI Transcript
Quantum-Si incorporated (QSI) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary shows a mixed financial performance: a notable revenue increase and improved gross margin, but a net loss persists. No significant strategic initiatives or operational updates were discussed, and management highlighted risks. The Q&A section did not provide any additional insights. The overall sentiment is neutral due to stable financial health but lacking clear positive catalysts or strategic advancements.
Quantum-Si incorporated (QSI) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call summary indicates positive developments such as successful prototype milestones, new product launches, and a strong financial position. The Q&A section reveals consistent consumable sales and strategic planning for the Proteus launch, despite some uncertainties in customer acquisition models and NIH funding. Overall, the company's strategic focus on product development and a strong balance sheet suggest a positive outlook, likely leading to a stock price increase.
Quantum-Si incorporated (QSI) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents mixed signals: revenue has decreased, and there are uncertainties in NIH funding, but there is optimism about product launches and market opportunities. The Q&A reveals management's evasiveness on key issues, adding uncertainty. Despite financial constraints, cost controls are evident. Strong financial metrics are offset by weak guidance and lack of clarity, leading to a neutral sentiment.
Quantum-Si incorporated (QSI) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary and Q&A reveal strong financial performance with an 84% revenue increase and a 58% gross margin. Management is optimistic about growth, especially in Q4, and is implementing flexible sales models to overcome capital constraints. The company is focused on innovation and market expansion, particularly in pharma and biotech. Despite some unclear responses, the overall sentiment is positive, supported by strategic product launches and a solid cash position. The stock price is likely to experience a positive movement in the next two weeks.
QSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
